We would love to hear your thoughts about our site and services, please take our survey here.
This share jumps both up and down constantly with no rime or reason. My only thought is that with Eli so close, are people pushing the price down to allow for a buyer to jump in. Is it the share allocation as part of the monies HEMO received or is it about to go catastrophic and MM's are hedging bets.
The 10-15% profiteer's will be enjoying the low buy price.
As Long Time Investors know, Vlad drops the RNS out of the blue and when we least expect it. Im no expert and been invested here since March last year and not bought and sold at the right times but learnt a lot and expect this will hit 10p+ in 2021. In reality, nearly double the current market price.
Markets are taking a beating which has a part to play, but when things do become quiet and no news, then traders jump ship and the price falls.
As others have said, one small bit of news that reflects positively will see this jump quickly. The loss you are seeing is only a paper loss unless you need to sell. Therefore sit and watch it unfold as with all shares, they have ups and downs.
The market all over is taking a battering and I couldn't resist buying at these levels. Sold a few shares elsewhere and bought in more to my pot.
It cant be long before Vlad drops an RNS and with the placement last year at 7p and so many strings in the pipeline, its only a matter of time before that RNS strikes a cord and the herd jump back in and this is 10p plus. Wont take much for that to happen and happy to place the long game with an average of 6p.
GLA
Considering only March they started this journey, the team are doing a cracking job and we forget how quick things move along. Just a reminder of those key dates we all enjoyed
18th March: SNG001 was identified in the WHO's Landscape analysis of therapeutics as at 17 February 2020 as the only Phase 2/Phase 3/Observational therapy delivered by the inhaled route (https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1).
31st March: Synairgen confirms commencement of dosing in trial of SNG001 in COVID-19
Southampton, UK - 30 April 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it has received approvals to extend the SG016 trial to patients with SARS-CoV-2 in the home environment. The objective is to initiate dosing with SNG001 (or placebo) earlier in the infection cycle, and before severe lower respiratory tract symptoms have developed. In due course, details of the design, implementation and timing of this novel study will be disclosed more fully.
The treatment of patients in the hospital setting in the SG016 study is progressing well, with more than 75 patients out of the target 100 now dosed with Synairgen's wholly-owned drug SNG001 or placebo. Results from this part of the study are still expected in June 2020.
Southampton, UK - 26 May 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that it has launched an expansion of the SG016 trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients to dose patients in the home setting. The expansion of the trial aims to dose patients earlier in the illness, within three days of symptoms developing.
Southampton, UK - 28 May 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce that recruitment of 100 hospitalised patients in its clinical trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients has now been completed.
Southampton, UK - 18 June 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces the expansion of the placebo-controlled home setting clinical trial of SNG001 (inhaled formulation of interferon-beta-1a) in patients with COVID-19. The trial has been expanded beyond the Southampton area to include patients across the majority of the UK.
Southampton, UK - 20 July 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company which originated from research at the University of Southampton, is pleased to announce positive results from its clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalised COVID-19 patients.
Simple Answer is the UK is what 60m and SNG can produce 100,000 treatments a month which means it can only support 2% of the population a year. Let alone every other country that needs SNG001.
Not everyone will want the vaccine and not everyone will benefit due to multiple reasons of mutation etc. But overall SNG will produce a significant income from SNG001 and it will support COPD patients and that market is huge also.
And we are all looking at the Covid Revenue and not even considered the COPD overlay and increasing supply.
The numbers are just phenomenal and we are talking about a few percentage points at the moment, think going back to hibernate until the spring and see what happens is a good plan.
An observation and not an answer i have seen, but if its 100,000 in production a month and a 14 day course at a cost of $3000, does that mean 100,000 divide by 14 * $3000 = $21.4m a month rather than £300,000,000 a month?
Vlad does like to keep us guessing but the RNS didnt have a followup but the team are making progress.
Eli Lilly & Covid are my expected updates soon enough.
Will continue to hold until news filters through and we see the SP where it should be.
GLA